Key areas of drug-based therapy in patients with corneoconjunctival xerosis

Abstract

In recent years, dry eye syndrome has attracted an increasing attention from ophthalmologists all over the world. This is largely due to the prevalence of the disease: the average number of people suffering from the disease is 14--15% of the adult population of the developed countries and up to 45% of patients first visiting ophthalmologist [2]. The other reason is severity of the clinical course and outcomes of some clinical types of the dry eye syndrome.

Keywords

• синдром «сухого глаза»
• фармакотерапия
• митохондриально-адресованные антиоксиданты
• визомитин®
• dry eye syndrome
• pharmacotherapy
• mitochondria-targeted antioxidants
• visomitin®